Clinical trials sponsored by Amgen

Phase breakdown

Conditions studied

Recruiting trials led by Amgen

• A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
  NCT06747949 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 174 locations
• A Phase 1 Trial of AMG 691 in Healthy Chinese and Japanese Volunteers
  NCT07745907 · Phase: Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location
• A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
  NCT06570798 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 58 locations
• A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
  NCT07005128 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 164 locations
• A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
  NCT05920356 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: All (male and female) · 418 locations
• A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
  NCT07037758 · Phase: Phase 1 · Ages: 18 Years to 90 Years · Sex: All (male and female) · 19 locations
• A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
  NCT07213674 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 151 locations
• A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
  NCT07590193 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
  NCT03633708 · Phase: Phase 3 · Ages: 0 Years to 18 Years · Sex: All (male and female) · 43 locations
• A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
  NCT07441252 · Phase: Phase 2 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 23 locations
• AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
  NCT07094113 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 39 locations
• Aimovig Pregnancy Exposure Registry
  NCT06150781 · Phase: Not specified · Ages: 18 Years to 99 Years · Sex: Female · 1 location
• Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
  NCT07575399 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 45 locations
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
  NCT07037433 · Phase: Phase 3 · Ages: 45 Years to 99 Years · Sex: All (male and female) · 782 locations
• Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
  NCT06613100 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 9 locations
• Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
  NCT07684235 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 87 locations
• Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
  NCT07684144 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 74 locations
• Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy
  NCT07226765 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 57 locations
• Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
  NCT07037459 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 1314 locations
• Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)
  NCT07778316 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 2 locations
• Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity
  NCT06585462 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 10 locations
• Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
  NCT07140900 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 16 locations
• Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
  NCT04221542 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 57 locations
• Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
  NCT06252649 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 291 locations
• Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
  NCT07531095 · Phase: Phase 1 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 27 locations
• Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
  NCT06598306 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 31 locations
• Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
  NCT07493512 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 11 locations

Common questions

How many trials is Amgen recruiting for?

Amgen is the lead sponsor of 27 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.